跳至主要内容
临床试验/NCT02930564
NCT02930564终止不适用

The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission

Wolfson Medical Center2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2017年1月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
10
试验地点
2
主要终点
number of patients with calprotetctin elevation

研究概览

简要总结

The Challenge study is a prospective, open label, pilot trial in patients in deep remission on dietary maintenance therapy.

The purpose of this study is to determine whether they can consume some of the products that were eliminated from their diet, named the Crohn's Disease Exclusion Diet (CDED), and to evaluate if low dose exposure is harmful.

详细描述

The investigators have previously hypothesized that Crohn's disease may occur via a sequence of events involving dysbiosis and genetically determined or environmentally acquired defects in innate immunity, and have further hypothesized that the mechanism of EEN for induction of remission acts by reducing exposure to dietary components that may cause an acquired bacterial clearance defect or generate dysbiosis.

Based on this premise, the investigators developed a new exclusion diet. This diet, named the Crohn's Disease Exclusion Diet (CDED) reduces exposure to all the components identified in rodent models as well as two components that are highly suspect but have not been investigated in models. This diet was evaluated for induction of remission through week 12 and succeeded in inducing remission in 70% of 47 selected patients.

The investigators have now progressed to three randomized controlled trials to evaluate the diet in different populations with different disease severity, and the results from the first RCT demonstrate a high remission rate in the CDED arm. However , to date the investigators have used the same diet for all patients. The investigators are now encountering patients on the diet in deep remission, but the investigators do not know if they can consume some of the products ( such as milk fat and gluten) that were eliminated. The investigators therefore are starting to challenge our patients in deep remission with low dose exposure to evaluate if low dose exposure is harmful. The investigators wish to document this and obtain stool samples for calprotetctin and microbiome to investigate these patients at a microbiological level as well.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
8 Years 至 20 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Established diagnosis of Crohn's disease.
  • Patients in sustained remission with PCDAI 0 > 6 months
  • Normal CRP (CRP<0.5), normal Calprotectin (<100)
  • Patients with uncomplicated disease
  • Signed informed consent

排除标准

  • Patients with active disease (PCDAI >10)
  • Patients with complicated disease (B2, B3)
  • Patients with recent onset use of an immunomodulator <12 weeks, or dose change in past 12 weeks.
  • Patients with current use of biologics.
  • Elevated CRP or Calprotetcin>100 at screening.

结局指标

主要结局

number of patients with calprotetctin elevation

时间窗: day 14 or 21

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Prof. Arie Levine

Prof

Wolfson Medical Center

研究点 (2)

Loading locations...

相似试验

The Challenge Study: A Dietary Personalization... | 临床试验